Skip to content
EmergingResearch compoundReference only

Declozindol

Experimental wakefulness-promoting research compound, a relative of mazindol; no peer-reviewed studies, not proven in humans.

NootropicPerformance BoosterEugeroicStimulantWakefulnessNorepinephrineDopamineAnti-fatigue

Pharmacology

ClassEugeroic · Stimulant · Wakefulness
Primary targetNorepinephrine transporter (NET), reuptake inhibition
Targets3 receptor targets
Half-lifeN/A
OnsetN/A
EvidenceReference only
Affected systemsNorepinephrineDopamineAnti-fatigue

Contents

DETAILED OVERVIEW

What is Declozindol?

Declozindol is a little-known experimental research compound described as a wakefulness-promoting agent and considered a chlorine-free relative of mazindol, a known stimulant. It is not approved anywhere and is sold as a substance not intended for human consumption.

Its proposed action is to block the reuptake of noradrenaline (a brain messenger involved in alertness and the stress response) into nerve cells, and it may also moderately affect the orexin system, which regulates wakefulness. There are no peer-reviewed animal or human studies and no reliable source for it, so all information is preliminary and proves neither its safety nor its effectiveness. In theory it could raise heart rate and blood pressure, and cause insomnia and loss of appetite; its long-term safety is unknown. There is no safety data for pregnancy and breastfeeding.

Mechanism

Selective NET reuptake inhibitor

Key target

Norepinephrine transporter (NET)

Evidence level

Reference-only (no human data)

Legal status

Unapproved research compound

Chemical formula

N/A (not reported)

Receptor profile

  • Norepinephrine transporter (NET)Strong
  • Orexin-2 receptor (OX2)Moderate
  • Dopamine transporter (DAT)Weak

Safety

Side effects, stop signs, contraindications

Side effects · 4

  • Raised heart rate and blood pressure (sympathomimetic effect of NET inhibition)
  • Insomnia, disturbed sleep (wakefulness-promoting profile)
  • Appetite suppression
  • Unknown long-term safety profile (no human data)

Contraindications · 5

  • No approved clinical use: strictly an experimental research compound with no human safety data
  • Cardiovascular disease (hypertension, arrhythmia): NET inhibition may raise heart rate and blood pressure
  • Anxiety disorders, insomnia: the wakefulness-promoting effect may worsen them
  • Pregnancy and breastfeeding: no reproductive safety data
  • With MAO inhibitors or other noradrenergic agents: additive sympathomimetic risk

Related Nootropics

Same therapeutic category

FAQ

FAQ

Declozindol is an almost entirely unknown experimental research compound, theoretically developed as a wakefulness and anti-fatigue agent, related to a known stimulant. It's important to be honest here: there is essentially no human data on it, every claim is theoretical or based on animal studies, so it should not be treated as an established or reliable substance.

Telegram

Have a question about Declozindol?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.